{"filing":{"accession_number":"0001628280-26-055940","cik":"0001576885","ticker":"ABOS","company_name":"Acumen Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"abos-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812.htm"},"events":[{"id":27016,"run_id":24582,"accession_number":"0001628280-26-055940","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Acumen Pharmaceuticals disclosed Q2 2026 financial results via press release furnished under Item 2.02, reporting a net loss of $32.7 million, R\u0026D expenses of $27.8 million, and a cash balance of $110.2 million as of June 30, 2026, along with clinical trial progress updates on ALTITUDE-AD and the EBD program.","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28352,"accession_number":"0001628280-26-055940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results (net loss of $32.7 million, R\u0026D expenses of $27.8 million, cash balance of $110.2 million) and business highlights including clinical trial progress on ALTITUDE-AD and the EBD program. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures. The filing includes condensed balance sheets, statements of operations, and cash flow statements typical of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:04:54.642804+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28353,"accession_number":"0001628280-26-055940","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation posted to the company's investor website. However, the supplemental exhibits (EX-99.1) contain Acumen's second quarter 2026 financial results and business highlights, including Q2 2026 net loss of $32.7 million, cash balance of $110.2 million as of June 30, 2026, and anticipated milestones for ALTITUDE-AD Phase 2 results expected in late 2026. This constitutes a quarterly earnings release with financial statements and operational updates material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:04:54.642804+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28352,"accession_number":"0001628280-26-055940","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 disclosing financial results (net loss of $32.7 million, R\u0026D expenses of $27.8 million, cash balance of $110.2 million) and business highlights including clinical trial progress on ALTITUDE-AD and the EBD program. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings disclosures. The filing includes condensed balance sheets, statements of operations, and cash flow statements typical of an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:04:54.642804+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-08-12"},{"id":28353,"accession_number":"0001628280-26-055940","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation posted to the company's investor website. However, the supplemental exhibits (EX-99.1) contain Acumen's second quarter 2026 financial results and business highlights, including Q2 2026 net loss of $32.7 million, cash balance of $110.2 million as of June 30, 2026, and anticipated milestones for ALTITUDE-AD Phase 2 results expected in late 2026. This constitutes a quarterly earnings release with financial statements and operational updates material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:04:54.642804+00:00","company_name":"Acumen Pharmaceuticals, Inc.","ticker":"ABOS","filing_date":"2026-08-12"}]}